What's in AbbVie's pipeline?

AbbVie has 199 drugs in our index: 66 marketed, 0 filed, 49 in Phase 3, 26 in Phase 2, 56 in Phase 1.

Which companies overlap with AbbVie's portfolio?

Top competitors by shared drug class: , Pfizer, Sanofi, AstraZeneca, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/abbvie.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

AbbVie — Portfolio Competitive Intelligence Brief

AbbVie (ABBV) pipeline: 66 marketed, 0 filed, 49 Phase 3, 26 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ABBV (NYSE) 66 marketed 0 filed 49 Phase 3 26 Phase 2 56 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Emrelis	TELISOTUZUMAB	marketed			Oncology	2025-01-01
FOSLEVODOPA	FOSLEVODOPA	marketed			Neuroscience	2024-01-01
FOSCARBIDOPA	FOSCARBIDOPA	marketed			Neuroscience	2024-01-01
Qulipta	ATOGEPANT	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	Neuroscience	2021-01-01
Skyrizi	RISANKIZUMAB	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	Immunology	2019-01-01
Ubrelvy	UBROGEPANT	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	Neuroscience	2019-01-01
Orilissa	ELAGOLIX	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	Pain	2018-01-01
Mavyret	GLECAPREVIR	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		Oncology	2017-01-01
Viberzi	ELUXADOLINE	marketed	mu-Opioid Receptor Agonist [EPC]	Mu-type opioid receptor	Pain	2015-01-01
Vraylar	CARIPRAZINE	marketed	Atypical Antipsychotic [EPC]	D(3) dopamine receptor	Metabolic	2015-01-01
Kybella	DEOXYCHOLIC ACID	marketed	Cytolytic Agent [EPC]	G-protein coupled bile acid receptor 1	Other	2015-01-01
Dalvance	DALBAVANCIN	marketed	Lipoglycopeptide Antibacterial		Infectious Disease	2014-01-01

Therapeutic area mix

Oncology · 19
Immunology · 16
Neuroscience · 15
Other · 9
Neurology · 6
Ophthalmology · 6
Metabolic · 6
Cardiovascular · 4
Infectious Disease · 4
Autoimmune diseases · 3

Recent regulatory actions (last 90 days)

2026-03-19 — FOSLEVODOPA · FDA · approved · US
2026-03-19 — FOSCARBIDOPA · FDA · approved · US
2026-02-26 — Dalvance · FDA · approved · US
2026-02-12 — Fml · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2028-09-17 — Viekira Pak (Copackaged) · 8501238 · US
2028-11-09 — Viekira Pak (Copackaged) · 9139536 · US
2029-05-17 — Viekira Pak (Copackaged) · 8188104 · US
2029-09-10 — Viekira Pak (Copackaged) · 8642538 · US
2030-05-26 — Venclexta · 9174982 · US
2030-06-10 — Mavyret · 10039754 · US
2030-06-10 — Mavyret · 10028937 · US
2030-06-10 — Viekira Pak (Copackaged) · 9006387 · US
2030-11-06 — Mavyret · 9586978 · US
2030-12-10 — Mavyret · 10028937*PED · US
2030-12-10 — Mavyret · 10039754*PED · US
2031-04-10 — Viekira Pak (Copackaged) · 8420596 · US
2031-04-10 — Viekira Pak (Copackaged) · 9044480 · US
2031-05-06 — Mavyret · 9586978*PED · US
2031-06-09 — Viekira Pak (Copackaged) · 8686026 · US
2031-06-27 — Venclexta · 8546399 · US
2031-11-21 — Venclexta · 10730873 · US
2032-01-19 — Mavyret · 8648037 · US
2032-01-29 — Venclexta · 8722657 · US
2032-04-13 — Viekira Pak (Copackaged) · 8691938 · US
2032-05-17 — Viekira Pak (Copackaged) · 10201541 · US
2032-05-17 — Viekira Pak (Copackaged) · 10201584 · US
2032-05-18 — Mavyret · 8937150 · US
2032-05-23 — Venclexta · 11369599 · US
2032-07-19 — Mavyret · 8648037*PED · US
2032-09-04 — Viekira Pak (Copackaged) · 8680106 · US
2032-09-04 — Viekira Pak (Copackaged) · 8466159 · US
2032-09-04 — Viekira Pak (Copackaged) · 8492386 · US
2032-09-04 — Viekira Pak (Copackaged) · 8685984 · US
2032-11-18 — Mavyret · 8937150*PED · US

Competitive overlap (companies sharing drug classes)

· 13 shared drug classes
Pfizer · 11 shared drug classes
Sanofi · 9 shared drug classes
AstraZeneca · 9 shared drug classes
GlaxoSmithKline · 6 shared drug classes
Allergan · 5 shared drug classes
AbbVie (prior sponsor, Abbott) · 4 shared drug classes
Bristol-Myers Squibb · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for AbbVie:

Cite this brief

Drug Landscape (2026). AbbVie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abbvie. Accessed 2026-05-13.